The metric gets the attention. The multiple is where the money is made.
Chad Brown, Founder, CommEx Advisors — a monthly read for investors and operators in life science tools and diagnostics. Revised edition, August 2026.
Same numbers, different price
Picture two Life Science Tools companies. Same revenue, same growth rate on the page, same tidy deck. One sells for six times revenue. The other for eleven. Nobody in the room is confused about the numbers. What the second buyer paid the premium for was not the revenue at all. It was the confidence that the revenue would keep showing up, quarter after quarter, long after the deal closed.
I have sat on both sides of that gap, and it took me a while to name what was really being priced. Here is the cleanest way I have found to say it.
Enterprise value = Multiple × Metric
Revenue, ARR, EBITDA — pick your metric. Everyone in the company obsesses over that number. Almost nobody manages the other side of the equation on purpose. The multiple is not a reward for the past quarter. It is a confidence score. It is the market pricing how believable your future is.
And in 2026, that belief is most of the value. Ocean Tomo has tracked this for years: intangibles now make up roughly ninety percent of the value of the S&P 500. The machines, the buildings, the inventory — all of it is a thin slice. The rest is the market betting that the commercial engine will keep producing. You are not selling what you built. You are selling the credibility of what you will build next.
Twelve is the new five
The bar for growth has moved. Bain put a number on it: twelve is the new five. For most of the last cycle a company growing around five percent a year could still deliver the return a sponsor underwrote, because cheap debt and a rising multiple did the rest of the work. Both of those are gone. Hitting the same return now takes something closer to twelve percent annual growth, earned rather than borrowed.
So growth is the lever that pays, and the bar just doubled. But not any growth. Growth a buyer can underwrite. Growth that shows up on schedule, from a system, not from a hero quarter that nobody can explain or repeat.
- **12%** annual growth is now needed to hit the return that 5% used to deliver. (Bain, Global PE Report 2026)
- **90%** of S&P 500 value is intangible — the market betting the commercial engine keeps producing. (Ocean Tomo)
Commercial execution is a multiplier, not a line item
Your science gets you in the room. It has to. But two companies with the same science walk out of that room valued very differently, and the difference is whether the commercial system can be trusted to deliver. That trust multiplies everything else you have built. A weak commercial engine does not just underperform. It discounts your science, your product, and your capital all at once, because it makes the future look like a guess.
What a buyer is actually scoring
The real question a buyer is asking is not how big is the number. It is how much do I believe the next eight quarters. That belief has a shape. I break it into four dimensions — the Predictability Quadrant© — and together they are what a board or a sponsor is really scoring when they set your multiple. Weakness on any one discounts the whole equation.
- **Forecast** — Do your commits match your actuals over time?
- **Pipeline** — Does your pipeline hold up under scrutiny, or look healthy until deals stall?
- **Execution** — Does your motion run on a repeatable system?
- **Coverage** — Is your coverage by design, or by luck?
A multiple is engineered, not exhorted
Here is the part leaders do not want to hear: you cannot exhort your way to a higher multiple. More pipeline reviews and a louder push at quarter end do not build predictability. They mask the absence of it. The multiple is engineered. You measure the commercial system honestly, you find the gap between the number you commit and the number you can defend, and you close it deliberately over time. It is the annual physical for the commercial engine: you run the baseline before anything hurts, not in the ambulance on the way to a raise or a sale.
If you are twelve to eighteen months from a raise or an exit, the multiple is being decided now, in the operating quarters nobody thinks of as diligence. The good news is that this is the most controllable lever you have. You cannot re-invent your science before the raise. You can make your commercial engine believable, and believable is what gets paid for. And if you are the investor underwriting one of these companies, this is your diligence lens too: the multiple you pay at entry and the one you exit at are both a bet on whether the commercial engine is believable, so score it at diligence and again in the quarterly portfolio review.
One caveat, stated plainly
The overstated version of this argument is everywhere and it does not survive contact with someone who prices companies for a living. Strong commercial execution does not, on its own, add turns to a multiple. Multiples are set largely by the comparable set, the growth rate, the revenue mix, and the market, and an experienced investor will tell you exactly that. What predictable execution does is remove a discount, and that is the more defensible claim.
It is also the more useful one. Weak execution produces a markdown that is reliable, quantifiable, and visible roughly eighteen months before an exit, which means it is visible in the operating quarters you are living in right now. The upside case and the downside case are the same mechanism viewed from opposite sides. Only one of them holds up under a counterargument, and it is the one that says the discount was avoidable.
Ask your team this month
Over the last four quarters, what did we commit and what did we deliver, quarter by quarter, side by side? If the gap surprises anyone in the room, that gap is the multiplier problem in one number.
Before you can build the multiplier, you have to measure it honestly, and most teams place themselves a notch higher than the evidence supports. That gap — between the number a team believes and the number it can defend — is where the discount lives. The Commercial Readiness Assessment© is the four-week diagnostic that closes it: a 0–100 CRI© Score, a pillar heatmap, and a prioritized 90-day roadmap, all while the dashboard still reads green. Operators run the baseline before a raise; investors run it at diligence or in a portfolio review.